Investigational drugs with or without chemotherapy for B-cell lymphoma
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests two new investigational drugs (SCTB35 and SCTB41) alone or with chemotherapy for people with B-cell lymphoma that hasn't responded to previous treatments. The goal is to see if these drugs can help shrink or control the lymphoma.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be between 18 and 80 years old.
- You must have a confirmed diagnosis of a B-cell lymphoma (a type of blood cancer).
- Your lymphoma must have come back or not responded after at least two prior treatments.
- You must have measurable or detectable disease, meaning the lymphoma can be seen on scans or tests.
- You need to be generally well enough to carry out daily activities (ECOG score 0 to 2).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach that combines radiation therapy, a stem cell transplant, and a special immune cell treatment (CAR-T) for people with an aggressive type of B-cell lymphoma that has returned or stopped responding to standard treatments. The goal is to see if this powerful combination can help control the cancer better.
This study tests a new experimental drug called SCTB35 for people with B-cell lymphoma that has come back or stopped responding to treatment. The drug is designed to target a protein on cancer cells (CD20) and may help your immune system fight the lymphoma.
This study tests a new drug called SCTB35 combined with two common chemotherapy drugs (gemcitabine and oxaliplatin) for patients with diffuse large B-cell lymphoma that has come back or stopped responding to previous treatment. The goal is to see if this combination is safe and helps shrink the cancer.
This trial tests an experimental cell therapy called KSVCBD for people with B-cell non-Hodgkin's lymphoma that has come back or not responded to standard treatments. The therapy targets two proteins (CD19 and BCMA) on cancer cells to help the immune system fight the disease.
This trial tests a new T-cell therapy (EB103) for people with B-cell non-Hodgkin's lymphoma that has come back or stopped responding to treatment. It aims to see if the therapy is safe and effective.
This trial tests a new combination of two investigational drugs (SCTB41 and SCTB39G), sometimes given with standard treatment, for advanced solid tumors. The goal is to see if this approach can shrink tumors and control the cancer, and it may be an option for people who have exhausted standard treatments.
Hear when a new NHL - Non-Hodgkin's Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.